Table 2.
Clinical trials of CAR-NK cell therapy. Ten trials are ongoing, and two trials are evaluating fourth generation CAR which expresses inducible apoptotic caspase 9, or inducible apoptotic caspase 9 with IL15.
| NCT Number | NK-Cell | Indication | Country | Group | Features |
|---|---|---|---|---|---|
| NCT03692767 | CD22 CAR-NK | Relapsed and Refractory B cell Leukemia | China | Allife Medical Science and Technology Co., Ltd | - |
| NCT03690310 | CD19 CAR-NK | Relapsed and Refractory B cell Leukemia | China | - | |
| NCT03398967 | Mesothelin CAR-NK | Epithelial Ovarian Cancer | China | - | |
| NCT03692663 | PSMA CAR-NK | Castration-Resistant Prostate Cancer | China | - | |
| NCT03824964 | CD19/CD22 CAR-NK | Relapsed and Refractory B cell Leukemia | China | - | |
| NCT03415100 | NKG2D-CAR-NK | Metastatic Solid Tumours | China | The Third Affiliated Hospital of Guangzhou Medical Univ. | - |
| NCT02944162 | CD33 CAR-NK | Relapsed/Refractory CD33+AML | China | PersonGen BioTherapeutics Co., Ltd | - |
| NCT02892695 | CD19 CAR-NK | CD19 Positive Leukemia and Lymphoma | China | - | |
| NCT03579927 | CD19 CAR-NK | B-cell Lymphoma | US | M.D. Anderson Cancer Center | Inducible apoptotic caspase 9 |
| NCT03056339 | CD19 CAR-NK | B Lymphoid Malignancies | US | Inducible apoptotic caspase 9 + IL15 |